Insulet (PODD) Stock Price, News & Analysis

Company Overview

Insulet Corporation is a medical technology company specializing in the design, development and commercialization of innovative insulin delivery systems for people with diabetes. The company’s flagship offering, the Omnipod Insulin Management System, is a tubeless, wearable insulin pump that combines a small, disposable Pod with a handheld Personal Diabetes Manager (PDM) or compatible smart device to automate and personalize insulin delivery. Insulet focuses on simplifying glycemic management and improving patient quality of life through intuitive device design and remote monitoring capabilities.

In addition to its original Omnipod system, Insulet has expanded its product portfolio to include the Omnipod DASH® System and Omnipod® 5 Automated Insulin Delivery System. Omnipod DASH employs Bluetooth technology to communicate with a secure, dedicated controller for on-demand insulin dosing, while Omnipod 5 integrates real-time continuous glucose monitoring (CGM) to automatically adjust insulin delivery in response to glucose readings. The company also offers digital tools such as data-sharing platforms and mobile apps that allow patients and care teams to track therapy, analyze trends and make informed treatment decisions.

Founded in 2000 and headquartered in Acton, Massachusetts, Insulet serves patients in North America, Western Europe, Australia, Japan and select other markets through a combination of direct commercial operations and strategic distribution partnerships. The company went public in 2007 and has since invested in global manufacturing and customer support infrastructure. Insulet’s leadership team is led by President and Chief Executive Officer Shacey Petrovic, who brings extensive experience in medical devices and technology commercialization. Under her direction, Insulet continues to pursue research and development initiatives aimed at expanding access to its insulin management solutions and advancing next-generation digital health offerings.

Key Stats

• Today's Range: $334.91 to $350.00
• 50-Day Range: $277.30 to $344.92
• 52-Week Range: $199.68 to $350.00
• Volume: 788,574 shs
• Average Volume: 672,061 shs
• Market Capitalization: $24.28 billion
• P/E Ratio: 104.84
• Dividend Yield: N/A
• Price Target: $332.71
• Consensus Rating: Moderate Buy

Insulet Stock Analysis - MarketRank™

Insulet scored higher than 86% of companies evaluated by MarketBeat, and ranked 155th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 16 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Insulet has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 26.79%

Earnings Growth

Earnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insulet is 104.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.21.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insulet is 104.84, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 82.57.

Price to Earnings Growth Ratio

Insulet has a PEG Ratio of 2.85. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Insulet has a P/B Ratio of 16.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.54% of the outstanding shares of Insulet have been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently increased by 2.29%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insulet does not currently pay a dividend.

Dividend Growth

Insulet does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -1.20

Percentage of Shares Shorted

2.54% of the outstanding shares of Insulet have been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently increased by 2.29%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.40

News Sentiment

Insulet has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Insulet this week, compared to 19 articles on an average week.

Search Interest

9 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.

MarketBeat Follows

2 people have added Insulet to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Insulet insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.39% of the stock of Insulet is held by insiders.

PODD Stock Analysis - Frequently Asked Questions

How have PODD shares performed this year?

Insulet's stock was trading at $261.07 on January 1st, 2025. Since then, PODD stock has increased by 32.1% and is now trading at $344.92.

How were Insulet's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) posted its earnings results on Thursday, August, 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The business's quarterly revenue was up 32.9% on a year-over-year basis.
Read the conference call transcript.

Who are Insulet's major shareholders?

Top institutional shareholders of Insulet include Vanguard Group Inc. (12.37%), Geode Capital Management LLC (2.74%), Norges Bank (1.47%) and Federated Hermes Inc. (1.03%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, John W Kapples, Wayde D Mcmillan, Mark N Field, Eric Benjamin, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Wayne AI Frederick, Shacey Petrovic and Luciana Borio.
View institutional ownership trends.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:PODD
• CIK: 1145197
• Web: www.insulet.com
• Phone: (978) 600-7000
• Fax: 978-600-0120
• Employees: 3,900
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Insulet: $332.71
• High Price Target: $380.00
• Low Price Target: $270.00
• Potential Upside/Downside: -3.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.29
• Trailing P/E Ratio: 104.84
• Forward P/E Ratio: 87.99
• P/E Growth: 2.85
• Net Income: $418.30 million
• Net Margins: 10.01%
• Pretax Margin: 11.47%
• Return on Equity: 23.78%
• Return on Assets: 9.30%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 2.26
• Quick Ratio: 1.81

Sales & Book Value

• Annual Sales: $2.07 billion
• Price / Sales: 11.72
• Cash Flow: $4.50 per share
• Price / Cash Flow: 76.61
• Book Value: $20.78 per share
• Price / Book: 16.60

Miscellaneous

• Outstanding Shares: 70,390,000
• Free Float: 70,118,000
• Market Cap: $24.28 billion
• Optionable: Optionable
• Beta: 1.36